Avoro Capital Advisors LLC
Avoro Capital Advisors LLC reported 26 holdings worth US$11.1B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Avoro Capital Advisors LLC reported 26 holdings worth US$11.1B as of Jun 30, 2026. Largest: United Therapeutics Corporation, Krystal Biotech, Inc. and Madrigal Pharmaceuticals, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 26
- Value as reported
- US$11.1B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| United Therapeutics Corporation | 2.78M | US$1.51B | 13.5% |
| Krystal Biotech, Inc. | 2.89M | US$1.07B | 9.6% |
| Madrigal Pharmaceuticals, Inc. | 1.83M | US$984M | 8.8% |
| Argenx Se | 1M | US$928M | 8.3% |
| Arrowhead Pharmaceuticals, Inc. | 11.4M | US$926M | 8.3% |
| Kymera Therapeutics, Inc. | 7.47M | US$857M | 7.7% |
| Revolution Medicines, Inc. | 2.3M | US$430M | 3.9% |
| Cytokinetics, Incorporated | 5M | US$426M | 3.8% |
| Celcuity Inc. | 3.4M | US$356M | 3.2% |
| Xenon Pharmaceuticals Inc. | 5.78M | US$349M | 3.1% |
| Definium Therapeutics, Inc. | 7.19M | US$338M | 3.0% |
| Vera Therapeutics, Inc. | 5.72M | US$246M | 2.2% |
| Taysha Gene Therapies, Inc. | 23.9M | US$163M | 1.5% |
| Ocular Therapeutix, Inc. | 12.5M | US$123M | 1.1% |
| Damora Therapeutics, Inc. | 3.78M | US$98.4M | 0.88% |
| Hemab Therapeutics Holdings, Inc. | 1.93M | US$70.7M | 0.63% |
| Viridian Therapeutics, Inc. | 2.5M | US$45.9M | 0.41% |
| Septerna, Inc. | 1.34M | US$44.8M | 0.40% |
| Avalo Therapeutics, Inc. | 2.33M | US$43.1M | 0.39% |
| Sensei Biotherapeutics, Inc. | 1.44M | US$36.1M | 0.32% |
| Whitehawk Therapeutics, Inc. | 2.85M | US$13.1M | 0.12% |
| Lexeo Therapeutics, Inc. | 1.49M | US$6.93M | 0.06% |
| Apellis Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Ascendis Pharma A/s | 0 | US$0 | 0.00% |
| Mannkind Corporation | 0 | US$0 | 0.00% |
| Soleno Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Terns Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related